Central diabetes insipidus (AVP deficiency) - chronic management
AVP-D · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Deficient vasopressin secretion (now termed AVP-deficiency) causing polyuria and polydipsia, from pituitary/hypothalamic damage. Long-term management centres on desmopressin with vigilance for hyponatraemia and adipsia.
Red flags
- Hyponatraemia with confusion/seizures (desmopressin excess/water retention)
- Adipsia with wide sodium swings
- Rapid-onset severe polyuria with a new pituitary lesion
- Coexisting untreated adrenal insufficiency masking diabetes insipidus
Assessment
Differential diagnosis
- Nephrogenic diabetes insipidus (AVP resistance)
- Primary polydipsia
- Osmotic diuresis (hyperglycaemia)
- Drug-induced polyuria
- Hypercalcaemia/hypokalaemia polyuria
Investigations
- Paired serum and urine osmolality
- Water deprivation test or copeptin-based testing (hypertonic saline/arginine stimulation)
- Serum sodium, glucose, calcium and potassium
- Pituitary MRI (loss of posterior bright spot, lesion)
- Anterior pituitary hormone screen
Management
- Confirm hypotonic polyuria and distinguish central from nephrogenic and primary polydipsia
- Use copeptin-based testing where available for accurate differentiation
- Image the pituitary/hypothalamus and screen anterior pituitary function
- Start desmopressin and titrate to control symptoms while allowing intermittent breakthrough diuresis
- Advise a regular weekly delayed/omitted dose to avoid chronic water retention
- Educate on thirst-guided fluid intake and recognising hyponatraemia
- Identify adipsic patients who cannot self-regulate and set fixed fluid/dose regimens
- Monitor sodium regularly, especially after dose changes or illness
- Provide a medical alert and sick-day guidance
- Treat any underlying lesion and replace other pituitary hormones as needed
Drugs & doses
Desmopressin 10-20 micrograms intranasally, or 100-400 micrograms PO 2-3 times daily, or 60-240 micrograms sublingual
Desmopressin 1-2 micrograms SC/IV for acute/inpatient use
Replacement of coexisting anterior pituitary deficiencies (e.g. hydrocortisone, levothyroxine)
Disposition
Manage with endocrinology and clear sick-day/surgery plans; admit for symptomatic sodium disturbance and give adipsic patients individualised fixed regimens.
Complications & pitfalls
- Iatrogenic hyponatraemia
- Severe hypernatraemic dehydration (especially adipsic patients)
- Hyponatraemic encephalopathy
- Mismanagement during intercurrent illness/surgery
Exam pearls
- Allow a regular breakthrough of dilute urine each week to prevent desmopressin-induced hyponatraemia
- Adipsic AVP-deficiency is dangerous because thirst no longer protects against sodium swings
- Untreated cortisol deficiency can mask diabetes insipidus, which unmasks after steroid replacement
- Copeptin testing is replacing the water deprivation test for accuracy
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.